Enanta Pharmaceuticals INC

Enanta Pharmaceuticals has entered into an Open Market Sale Agreement to offer and sell up to $75 million of its common stock through Jefferies LLC.

Enanta Pharmaceuticals announced the advancement of its zelicapavir clinical development program for Respiratory Syncytial Virus (RSV), including plans for registrational trials in high-risk adults and pediatric patients.

Enanta Pharmaceuticals reported its fiscal second quarter 2026 financial results, highlighting progress in its immunology and virology pipelines, alongside updates on ongoing litigation.

Enanta Pharmaceuticals' patent infringement lawsuit against Pfizer regarding Paxlovid is moving forward with oral arguments scheduled for May 11, 2026, at the Federal Circuit.

Enanta Pharmaceuticals' stockholders approved an increase of 1.6 million shares to its 2019 Equity Incentive Plan and re-elected two Class I directors at its Annual Meeting.

Enanta Pharmaceuticals announced improved fiscal year 2025 financial results, positive clinical data for its RSV programs, and advanced two immunology candidates, extending its cash runway into fiscal 2029.

Enanta Pharmaceuticals reported a Q2 2026 increase in royalty revenue driven by higher HCV sales, while research and development expenses decreased due to strategic timing of RSV trials.

Enanta Pharmaceuticals reported a significantly reduced net loss in Q1 2026, driven by lower R&D and G&A expenses, while maintaining a strong cash runway into fiscal 2029.

Enanta Pharmaceuticals reported a significant reduction in net loss for the nine months ended June 30, 2025, driven by lower operating expenses, and projects its cash resources will fund operations into fiscal 2028.

Enanta Pharmaceuticals reports a decrease in revenue for Q2 2025 due to lower HCV sales, while highlighting progress in RSV and immunology programs.

Enanta Pharmaceuticals announces its financial results for the quarter ended December 31, 2024, and provides updates on its virology and immunology programs, particularly focusing on RSV.

Enanta Pharmaceuticals reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and financial position.

Enanta Pharmaceuticals, Inc. reported its fiscal year 2025 results, highlighting progress in its RSV and immunology pipelines, alongside a decrease in HCV royalty revenue and continued operating losses.

Enanta Pharmaceuticals' 10-K filing highlights its ongoing clinical programs in RSV and preclinical efforts in immunology, while also detailing its financial performance and reliance on AbbVie royalties.

Enanta Pharmaceuticals director Terry Vance was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Lesley Russell received a grant of 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Kristine Peterson was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Yujiro S. Hata received a grant of 20,000 stock options with a $14.17 exercise price, vesting over one year.

Enanta Pharmaceuticals Director Mark G. Foletta was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Bruce L.A. Carter was granted 20,000 stock options with an exercise price of $14.17.

Enanta Pharmaceuticals, Inc. announced the agenda for its Annual Meeting of Stockholders on March 11, 2026, including director elections and equity plan amendments.

Enanta Pharmaceuticals, Inc. will hold its 2026 Annual Meeting to elect directors, approve a 1.6 million share increase for its equity incentive plan, and ratify executive compensation and auditor appointment.

Enanta Pharmaceuticals announces its annual meeting of stockholders to be held on March 13, 2025, with key proposals including director elections, equity incentive plan amendment, executive compensation votes, and auditor ratification.

Enanta Pharmaceuticals is asking stockholders to approve an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance by 800,000 at the virtual 2025 Annual Meeting on March 13, 2025.

Enanta Pharmaceuticals, Inc. CEO, Dr. Jay R. Luly, has increased his beneficial ownership to 7.7% through a recent open market share purchase and the vesting of performance share units.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Enanta Pharmaceuticals Inc. following an internal realignment.

Deep Track Capital, LP and affiliated entities have reported a 6.78% beneficial ownership stake in Enanta Pharmaceuticals Inc. as of December 31, 2025.

Farallon Capital Management entities and individuals updated their beneficial ownership in Enanta Pharmaceuticals Inc., reflecting internal management changes within Farallon.

Millennium Management and affiliated entities have filed an amended Schedule 13G, reporting a 2.3% beneficial ownership in Enanta Pharmaceuticals, Inc. as of December 31, 2025.

Millennium Management and affiliates report a 4.1% beneficial ownership in Enanta Pharmaceuticals as of September 30, 2025.

Janus Henderson Group PLC and its affiliates have reported a significant beneficial ownership stake of 12.1% in Enanta Pharmaceuticals Inc.